This study aims to evaluate the treatment outcomes according to the risk groups of patients with Stage 1 endometrial cancer and to investigate the effects of the risks associated with the disease in the control of the disease.
METHODS
Three hundred and ninety patients who were treated with the indication of endometrial cancer in our
clinic were evaluated with the approval of the ethics committee. The data of 114 patients who were
evaluated retrospectively between 2014-2018.
RESULTS
In patients with a median age of 58 (35-89) years, histological distribution of pathologies revealed the
presence of cases of the 107 endometrioid adenocarcinoma (93%), two serous (1.7%), two clear cells
(1.7%), one mucinous (0.8%) carcinomas and two (1.7%) carcinosarcoma. High risk was detected in 14
(12.28%), high to intermediate risk in nine (7%), intermediate risk in 35 (30.7%), and low-risk in 56 p
(49%) patients. Recurrence developed in five (4%) patients whose survival was found to be statistically
significantly lower than those without recurrence (logrank: 41.74 p=0.0001). Five -year survival rate was
95% and the mean (±SD) survival time was 78.46±1.27 months.
CONCLUSION
In the treatment of Stage 1 endometrial cancer, the survival rates achieved in our disease-recurrence
group was statistically significantly lower than those who did not develop recurrences (logrank: 41.74
p=0.0001).